FindTrial
Sign In

The Research of Effect of Therapy of Invigorating the Kidney, Activating Blood Circulation, Eliminating Sputum and Clearing Heat on Polycystic Ovarian Syndrome by Regulating the Inflammation Signal Transduction Pathway of NF-?B

The Research of Effect of Therapy of Invigorating the Kidney, Activating Blood Circulation, Eliminating Sputum and Clearing Heat on Polycystic Ovarian Syndrome by Regulating the Inflammation Signal Transduction Pathway of NF-?B

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003266
Enrollment
Unknown
Registered
2013-06-12
Start date
2013-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovarian Syndrome

Interventions

Experimental group:Berberine tablets
The control group:Placebo

Sponsors

Heilongjiang University of Chinese Medicine the First affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. conform to the diagnostic criteria of nonalcoholic fatty liver disease and polycystic ovary syndrome, is willing to cooperate; 2. aged from 20 to 35 years old; 3. tolerated Chinese medicine treatment.

Exclusion criteria

Exclusion criteria: 1. high blood prolactin, Cushing's syndrome, congenital adrenal hyperplasia, abnormal function of thyroid gland, adrenal or ovarian secretion of androgens tumor, etc.; 2. merge serious primary diseases such as heart, liver, kidney, and psychiatric patients; 3. three months used hormone therapy patients; 4. hepatitis b, hepatitis c, large amounts of alcohol intake and chronic liver disease; 5. pregnancy during the study period falls off.

Design outcomes

Primary

MeasureTime frame
B ultrasonic of The liver;Sex hormones;HCG stimulation test;Glucose tolerance test;Insulin release test;Liver function indicators;Cholesterol targets;Ovulation rate;Ovarian and endometrial ultrasound;Body mass index (BMI);waist-to-hip ratio (WHR);waist-to-hip ratio (WHR);The clinical symptom;—

Countries

China

Contacts

Public ContactShu-fen Zhang
zhsfen@hotmail.com+86 13934559411

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026